Latest From Debiopharm Group
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.
- Large Molecule
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Debio Group
- Western Europe
- Parent & Subsidiaries
- Debiopharm Group
- Senior Management
Rolland-Yves Mauvernay, Co-Pres.
Thierry Mauvernay, Co-Pres.
- Contact Info
Phone: (41) 21 321 0111
Chemin Messidor 5-7
P.O. Box 5911 Lausanne, CH-1002
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.